enow.com Web Search

  1. Ads

    related to: als drugs in phase 3

Search results

  1. Results from the WOW.Com Content Network
  2. ALS drug Relyvrio withdrawn from market after failed clinical ...

    www.aol.com/als-drug-relyvrio-withdrawn-market...

    Results from a large Phase 3 clinical trial released in early March showed that Relyvrio did not outperform a placebo in improving participants’ ALS functional scale, a measure of their ability ...

  3. Amylyx Pharma to remove ALS drug from US, Canada markets - AOL

    www.aol.com/news/amylyx-pharma-remove-als-drug...

    The ALS drug, branded Relyvrio, was approved in 2022 after lobbying by patient groups who pointed to limited options to treat the potentially fatal disease. ALS causes progressive paralysis and ...

  4. 3K3A-Activated Protein C - Wikipedia

    en.wikipedia.org/wiki/3K3A-Activated_Protein_C

    3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech. [1] It is also being assessed for the treatment of Alzheimer's disease. [2] It is the subject of RHAPSODY, a phase II trial to determine safety and tolerability. [3]

  5. Sotuletinib - Wikipedia

    en.wikipedia.org/wiki/Sotuletinib

    Sotuletinib (BLZ945) is an experimental drug in development for the treatment of amyotrophic lateral sclerosis (ALS). It works as a colony-stimulating factor 1 ( CSF1 ) receptor inhibitor. [ 1 ] [ 2 ] [ 3 ]

  6. Amylyx's approved ALS drug flunks crucial test, shares dive - AOL

    www.aol.com/news/amylyxs-als-drug-fails-stage...

    (Reuters) -Amylyx Pharmaceuticals is considering withdrawing its treatment for amyotrophic lateral sclerosis from the market after the drug failed to slow disease progression in a late-stage trial ...

  7. Dexpramipexole - Wikipedia

    en.wikipedia.org/wiki/Dexpramipexole

    The drug was initially investigated in ALS by Knopp Biosciences and Biogen Idec. A 2010 Phase II clinical trial showed a slowing of ALS disease progression and mortality benefits. [8] In January 2013, Biogen Idec discontinued its development of dexpramipexole in ALS due to lack of efficacy in the Phase III study. [9]

  8. Blarcamesine - Wikipedia

    en.wikipedia.org/wiki/Blarcamesine

    The drug was developed by Anavex Life Sciences. [1] As of August 2024, it is in preregistration for Alzheimer's disease, phase 2/3 clinical trials for fragile X syndrome and Rett syndrome, phase 2 trials for Parkinson's disease, and phase 1 trials for Angelman syndrome and infantile spasms. [1]

  9. MNOV: Positive FDA Feedback on ALS Phase 3 Plan… - AOL

    www.aol.com/news/mnov-positive-fda-feedback-als...

    On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral ...

  1. Ads

    related to: als drugs in phase 3